New Delhi: Results of the Interim Analysis of the Third Phase Program conducted Oxford The vaccine is safe and effective in preventing symptomatic Covid-19 and protects against chronic disease and hospitalization, the University of AZD1222 said in The Lancet on Wednesday.
The interim analysis for efficacy was based on 131 symptomatic infections performed by 11,636 participants from the UK and Brazil trials Oxford University.
As announced on November 23, the primary endpoint of the program’s statistical plan based on a collection of two dosing regimens has shown that the vaccine is 70.4 percent effective at preventing symptomatic Covid-19 occurring more than 14 days after receiving two doses. Vaccine. The end point of the secondary efficacy of acute disease prevention was that the vaccine group exhibited no cases of acute infections or hospitalization.
Further analysis of the efficacy regimen showed that when the vaccine was administered in two full doses, the efficacy of the vaccine was 62.1 per cent and 90.0 per cent of the participants after receiving half the dose.
Vaccine efficacy is assessed on the secondary end point of early prevention of acute disease after the first dose. No hospitalizations or severe cases of Covid-19 were observed 21 days after the first dose of the vaccine. Ten people who participated in the control group were hospitalized because of Kovid-19, two of whom were diagnosed with a fatal case.
More data will be collected as part of the upcoming preliminary analysis, and future follow-up, efficacy reading, and long-term presentation of vaccine efficacy.
The safety data published so far are from more than 20,000 participants enrolled in four clinical trials in the UK and Brazil, and in addition from South Africa (COV005). The Lancet publication affirms that AZD1222 is well tolerated and that there are no serious safety incidents related to the vaccine.
Participants were from diverse ethnic and geographical groups with healthy or stable medical conditions. This analysis provides 74,434 person-month follow-up safety data after the first dose (mean 3.4 months) and 29,097 person-month follow-up after two doses (average 2.0). Overall reported rates of serious adverse events were 0.7 per cent in the vaccine group and 0.8 per cent in the control group.
Andrew Pollard, Director Oxford Vaccine Group and Chief Investigator Oxford The vaccine trial, said: “Today, we have published an interim analysis of the third phase of the trial and showed that this new vaccine has a good safety record and efficacy against coronavirus.
Chief Executive Officer Pascal Soriot said: “Today’s peer-reviewed publication enables its full disclosure Oxford Program interim analysis. The results show that the vaccine is effective against covid-19, particularly in acute infections and no hospitalization in the vaccine group, as well as safe and well-tolerated. We have begun submitting data to regulatory authorities around the world for early approval, and our global supply chains are up and running, delivering hundreds of millions of doses quickly, with no profit globally. ”
As part of their ongoing review of vaccine data for temporary use or conditional approval during this health crisis, it has already begun submitting data to regulatory authorities around the world. The company is seeking an emergency use list from the World Health Organization for quick access to vaccine availability in low-income countries.
The company is making rapid progress in production with a capacity of 3 billion doses of vaccine in 2021, pending regulatory approval. The vaccine can be stored, transported and maintained under normal refrigerated conditions (2-8 degrees Celsius / 36-46 degrees Fahrenheit) for at least six months and maintained in existing health care systems.
AstraZeneca engages with governments, multilateral organizations and collaborators around the world to ensure broad and equal access to the vaccine without any benefit to the epidemic.


Similar Posts